Fasting and nonfasting lipid and apoB-concentrations at baseline and postintervention treatment with metformin, fish oil or fish oil-metformin for 12 weeks in women with PCOS
| . | . | Metformin (n = 8) . | . | Fish oil (n = 13) . | . | Fish oil-metformin (n = 8) . | . |
|---|---|---|---|---|---|---|---|
| . | Baseline all groups (n = 29) . | Baseline . | Post(%) . | Baseline . | Post (%) . | Baseline . | Post (%) . |
| TG, mmol/L TG, AUC TG, iAUC | 2.5 ± 0.2 2459 ± 260 825 ± 128 | 2.2 ± 0.2 2388 ± 583 955 ± 217 | 2.1 ± 0.2 (−5) 2154 ± 626 (10) 742 ± 272 (−12) | 2.5 ± 0.2 2620 ± 350 911 ± 237 | 2.0 ± 0.1 (−20) 2227 ± 178 (−15) 734 ± 92 (−20) | 2.7 ± 0.5 2599 ± 521 783 ± 237 | 1.8 ± 0.2 (−43)* 1570 ± 258 (−40) 360 ± 63 (−54) |
| TC, mmol/L | 5.3 ± 0.2 | 5.4 ± 0.2 | 4.6 ± 0.2 (−10)* | 5.3 ± 0.4 | 5.2 ± 0.3 (−2) | 5.4 ± 0.3 | 5.0 ± 0.4 (−8) |
| HDL-C, mmol/L | 1.0 ± 0.0 | 1.1 ± 0.1 | 1.0 ± 0.1 (−10) | 1.0 ± 0.1 | 0.99 ± 0.1 (0) | 0.9 ± 0.05 | 1.0 ± 0.1 (10) |
| LDL-C, mmol/L | 3.4 ± 0.2 | 3.4 ± 0.2 | 2.9 ± 0.2 (−15) | 3.4 ± 0.4 | 3.5 ± 0.3 (3) | 3.3 ± 0.2 | 3.3 ± 0.3 (0) |
| Non-HDL-C, mmol/L ApoB48, μg/mL ApoB48, AUC ApoB48, iAUC ApoB100, g/mL ApoB100, AUC ApoB100, iAUC | 4.6 ± 0.2 24.6 ± 2.4 188.3 ± 17.4 43.8 ± 6.2 2.8 ± 0.2 25185 ± 2140 5682 ± 857 | 4.2 ± 0.2 22.3 ± 4.8 187.1 ± 34.4 40.1 ± 9.5 2.8 ± 0.20 27240 ± 4824 6810 ± 1900 | 3.6 ± 0.2 (−15) 21.4 ± 5.5 (4) 174.1 ± 25.5 (−7) 37.2 ± 5.8 (−7) 3.5 ± 0.8 (20) 26996 ± 5873 (−1) 7017 ± 1352 (3) | 4.7 ± 0.4 21.7 ± 2.7 189.5 ± 14.7 45.4 ± 8.0 2.9 ± 0.3 24727 ± 2155 5251 ± 1061 | 4.5 ± 0.3 (−4) 18.5 ± 2.9 (−15) 170.5 ± 17.8 (−10) 38.6 ± 9.6 (−15) 3.1 ± 0.5 (7) 21811 ± 2908 (−12) 4963 ± 1735 (−5) | 4.7 ± 0.2 26.3 ± 6.5 199.7 ± 60.0 42.6 ± 18.2 2.8 ± 0.3 23779 ± 6403 5487 ± 2209 | 4.3 ± 0.3 (−9) 15.7 ± 1.2 (−40) 135.8 ± 12.6 (−32) 31.1 ± 6.5 (−17) 2.7 ± 0.3 (4) 20238 ± 2782 (−15) 4800 ± 1046 (−12) |
| . | . | Metformin (n = 8) . | . | Fish oil (n = 13) . | . | Fish oil-metformin (n = 8) . | . |
|---|---|---|---|---|---|---|---|
| . | Baseline all groups (n = 29) . | Baseline . | Post(%) . | Baseline . | Post (%) . | Baseline . | Post (%) . |
| TG, mmol/L TG, AUC TG, iAUC | 2.5 ± 0.2 2459 ± 260 825 ± 128 | 2.2 ± 0.2 2388 ± 583 955 ± 217 | 2.1 ± 0.2 (−5) 2154 ± 626 (10) 742 ± 272 (−12) | 2.5 ± 0.2 2620 ± 350 911 ± 237 | 2.0 ± 0.1 (−20) 2227 ± 178 (−15) 734 ± 92 (−20) | 2.7 ± 0.5 2599 ± 521 783 ± 237 | 1.8 ± 0.2 (−43)* 1570 ± 258 (−40) 360 ± 63 (−54) |
| TC, mmol/L | 5.3 ± 0.2 | 5.4 ± 0.2 | 4.6 ± 0.2 (−10)* | 5.3 ± 0.4 | 5.2 ± 0.3 (−2) | 5.4 ± 0.3 | 5.0 ± 0.4 (−8) |
| HDL-C, mmol/L | 1.0 ± 0.0 | 1.1 ± 0.1 | 1.0 ± 0.1 (−10) | 1.0 ± 0.1 | 0.99 ± 0.1 (0) | 0.9 ± 0.05 | 1.0 ± 0.1 (10) |
| LDL-C, mmol/L | 3.4 ± 0.2 | 3.4 ± 0.2 | 2.9 ± 0.2 (−15) | 3.4 ± 0.4 | 3.5 ± 0.3 (3) | 3.3 ± 0.2 | 3.3 ± 0.3 (0) |
| Non-HDL-C, mmol/L ApoB48, μg/mL ApoB48, AUC ApoB48, iAUC ApoB100, g/mL ApoB100, AUC ApoB100, iAUC | 4.6 ± 0.2 24.6 ± 2.4 188.3 ± 17.4 43.8 ± 6.2 2.8 ± 0.2 25185 ± 2140 5682 ± 857 | 4.2 ± 0.2 22.3 ± 4.8 187.1 ± 34.4 40.1 ± 9.5 2.8 ± 0.20 27240 ± 4824 6810 ± 1900 | 3.6 ± 0.2 (−15) 21.4 ± 5.5 (4) 174.1 ± 25.5 (−7) 37.2 ± 5.8 (−7) 3.5 ± 0.8 (20) 26996 ± 5873 (−1) 7017 ± 1352 (3) | 4.7 ± 0.4 21.7 ± 2.7 189.5 ± 14.7 45.4 ± 8.0 2.9 ± 0.3 24727 ± 2155 5251 ± 1061 | 4.5 ± 0.3 (−4) 18.5 ± 2.9 (−15) 170.5 ± 17.8 (−10) 38.6 ± 9.6 (−15) 3.1 ± 0.5 (7) 21811 ± 2908 (−12) 4963 ± 1735 (−5) | 4.7 ± 0.2 26.3 ± 6.5 199.7 ± 60.0 42.6 ± 18.2 2.8 ± 0.3 23779 ± 6403 5487 ± 2209 | 4.3 ± 0.3 (−9) 15.7 ± 1.2 (−40) 135.8 ± 12.6 (−32) 31.1 ± 6.5 (−17) 2.7 ± 0.3 (4) 20238 ± 2782 (−15) 4800 ± 1046 (−12) |
Values are presented as mean ± SEM and variables were normally distributed. Post (%) represents mean percentage change from baseline within group. AUC and iAUC represent nonfasting response following a high-fat meal test.
Abbreviations: AUC, area under the curve; HDL-C, high-density lipoprotein cholesterol; iAUC, incremental area under the curve; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol, TC, total cholesterol; TG, triglycerides.
Fasting and nonfasting lipid and apoB-concentrations at baseline and postintervention treatment with metformin, fish oil or fish oil-metformin for 12 weeks in women with PCOS
| . | . | Metformin (n = 8) . | . | Fish oil (n = 13) . | . | Fish oil-metformin (n = 8) . | . |
|---|---|---|---|---|---|---|---|
| . | Baseline all groups (n = 29) . | Baseline . | Post(%) . | Baseline . | Post (%) . | Baseline . | Post (%) . |
| TG, mmol/L TG, AUC TG, iAUC | 2.5 ± 0.2 2459 ± 260 825 ± 128 | 2.2 ± 0.2 2388 ± 583 955 ± 217 | 2.1 ± 0.2 (−5) 2154 ± 626 (10) 742 ± 272 (−12) | 2.5 ± 0.2 2620 ± 350 911 ± 237 | 2.0 ± 0.1 (−20) 2227 ± 178 (−15) 734 ± 92 (−20) | 2.7 ± 0.5 2599 ± 521 783 ± 237 | 1.8 ± 0.2 (−43)* 1570 ± 258 (−40) 360 ± 63 (−54) |
| TC, mmol/L | 5.3 ± 0.2 | 5.4 ± 0.2 | 4.6 ± 0.2 (−10)* | 5.3 ± 0.4 | 5.2 ± 0.3 (−2) | 5.4 ± 0.3 | 5.0 ± 0.4 (−8) |
| HDL-C, mmol/L | 1.0 ± 0.0 | 1.1 ± 0.1 | 1.0 ± 0.1 (−10) | 1.0 ± 0.1 | 0.99 ± 0.1 (0) | 0.9 ± 0.05 | 1.0 ± 0.1 (10) |
| LDL-C, mmol/L | 3.4 ± 0.2 | 3.4 ± 0.2 | 2.9 ± 0.2 (−15) | 3.4 ± 0.4 | 3.5 ± 0.3 (3) | 3.3 ± 0.2 | 3.3 ± 0.3 (0) |
| Non-HDL-C, mmol/L ApoB48, μg/mL ApoB48, AUC ApoB48, iAUC ApoB100, g/mL ApoB100, AUC ApoB100, iAUC | 4.6 ± 0.2 24.6 ± 2.4 188.3 ± 17.4 43.8 ± 6.2 2.8 ± 0.2 25185 ± 2140 5682 ± 857 | 4.2 ± 0.2 22.3 ± 4.8 187.1 ± 34.4 40.1 ± 9.5 2.8 ± 0.20 27240 ± 4824 6810 ± 1900 | 3.6 ± 0.2 (−15) 21.4 ± 5.5 (4) 174.1 ± 25.5 (−7) 37.2 ± 5.8 (−7) 3.5 ± 0.8 (20) 26996 ± 5873 (−1) 7017 ± 1352 (3) | 4.7 ± 0.4 21.7 ± 2.7 189.5 ± 14.7 45.4 ± 8.0 2.9 ± 0.3 24727 ± 2155 5251 ± 1061 | 4.5 ± 0.3 (−4) 18.5 ± 2.9 (−15) 170.5 ± 17.8 (−10) 38.6 ± 9.6 (−15) 3.1 ± 0.5 (7) 21811 ± 2908 (−12) 4963 ± 1735 (−5) | 4.7 ± 0.2 26.3 ± 6.5 199.7 ± 60.0 42.6 ± 18.2 2.8 ± 0.3 23779 ± 6403 5487 ± 2209 | 4.3 ± 0.3 (−9) 15.7 ± 1.2 (−40) 135.8 ± 12.6 (−32) 31.1 ± 6.5 (−17) 2.7 ± 0.3 (4) 20238 ± 2782 (−15) 4800 ± 1046 (−12) |
| . | . | Metformin (n = 8) . | . | Fish oil (n = 13) . | . | Fish oil-metformin (n = 8) . | . |
|---|---|---|---|---|---|---|---|
| . | Baseline all groups (n = 29) . | Baseline . | Post(%) . | Baseline . | Post (%) . | Baseline . | Post (%) . |
| TG, mmol/L TG, AUC TG, iAUC | 2.5 ± 0.2 2459 ± 260 825 ± 128 | 2.2 ± 0.2 2388 ± 583 955 ± 217 | 2.1 ± 0.2 (−5) 2154 ± 626 (10) 742 ± 272 (−12) | 2.5 ± 0.2 2620 ± 350 911 ± 237 | 2.0 ± 0.1 (−20) 2227 ± 178 (−15) 734 ± 92 (−20) | 2.7 ± 0.5 2599 ± 521 783 ± 237 | 1.8 ± 0.2 (−43)* 1570 ± 258 (−40) 360 ± 63 (−54) |
| TC, mmol/L | 5.3 ± 0.2 | 5.4 ± 0.2 | 4.6 ± 0.2 (−10)* | 5.3 ± 0.4 | 5.2 ± 0.3 (−2) | 5.4 ± 0.3 | 5.0 ± 0.4 (−8) |
| HDL-C, mmol/L | 1.0 ± 0.0 | 1.1 ± 0.1 | 1.0 ± 0.1 (−10) | 1.0 ± 0.1 | 0.99 ± 0.1 (0) | 0.9 ± 0.05 | 1.0 ± 0.1 (10) |
| LDL-C, mmol/L | 3.4 ± 0.2 | 3.4 ± 0.2 | 2.9 ± 0.2 (−15) | 3.4 ± 0.4 | 3.5 ± 0.3 (3) | 3.3 ± 0.2 | 3.3 ± 0.3 (0) |
| Non-HDL-C, mmol/L ApoB48, μg/mL ApoB48, AUC ApoB48, iAUC ApoB100, g/mL ApoB100, AUC ApoB100, iAUC | 4.6 ± 0.2 24.6 ± 2.4 188.3 ± 17.4 43.8 ± 6.2 2.8 ± 0.2 25185 ± 2140 5682 ± 857 | 4.2 ± 0.2 22.3 ± 4.8 187.1 ± 34.4 40.1 ± 9.5 2.8 ± 0.20 27240 ± 4824 6810 ± 1900 | 3.6 ± 0.2 (−15) 21.4 ± 5.5 (4) 174.1 ± 25.5 (−7) 37.2 ± 5.8 (−7) 3.5 ± 0.8 (20) 26996 ± 5873 (−1) 7017 ± 1352 (3) | 4.7 ± 0.4 21.7 ± 2.7 189.5 ± 14.7 45.4 ± 8.0 2.9 ± 0.3 24727 ± 2155 5251 ± 1061 | 4.5 ± 0.3 (−4) 18.5 ± 2.9 (−15) 170.5 ± 17.8 (−10) 38.6 ± 9.6 (−15) 3.1 ± 0.5 (7) 21811 ± 2908 (−12) 4963 ± 1735 (−5) | 4.7 ± 0.2 26.3 ± 6.5 199.7 ± 60.0 42.6 ± 18.2 2.8 ± 0.3 23779 ± 6403 5487 ± 2209 | 4.3 ± 0.3 (−9) 15.7 ± 1.2 (−40) 135.8 ± 12.6 (−32) 31.1 ± 6.5 (−17) 2.7 ± 0.3 (4) 20238 ± 2782 (−15) 4800 ± 1046 (−12) |
Values are presented as mean ± SEM and variables were normally distributed. Post (%) represents mean percentage change from baseline within group. AUC and iAUC represent nonfasting response following a high-fat meal test.
Abbreviations: AUC, area under the curve; HDL-C, high-density lipoprotein cholesterol; iAUC, incremental area under the curve; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol, TC, total cholesterol; TG, triglycerides.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
